Minerva Neurosciences, Inc. — Form 8-K
Filed August 7, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Minerva reported Q2 2026 results with R&D expenses of $7.2M (vs. $1.3M YoY) driven by the ongoing C19 Phase 3 trial of roluperidone for schizophrenia negative symptoms, enrolling 380 patients across ~40 sites; topline Phase A data expected 2H 2027. Cash position fell from $82.4M (Dec 31, 2025) to $75.4M (June 30, 2026); adjusted non-GAAP net loss was $7.8M for Q2 2026 vs. $3.0M loss in Q2 2025. GAAP figures distorted by $232.7M warrant liability (non-cash, mark-to-market).
Why this rating
Phase 3 advancement is clinically positive but company faces real cash burn ($7M+ per quarter adjusted) against $7M market cap—runway concerns offset by on-track trial execution; routine progress for clinical-stage biotech.
See more from August 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.